机构持仓方面，截止2025年9月30日，博拓生物十大流通股东中，广发价值核心混合A（010377）退出 十大流通股东之列。 声明：市场有风险，投资需谨慎。本文基于第三方数据库自动发布，不代表新浪财经观点，任何在本文 出现的信息均只作为参考，不构成个人投资建议。如有出入请以实际公告为准。如有疑问，请联系 biz@staff.sina.com.cn。 责任编辑：小浪快报 资料显示，杭州博拓生物科技股份有限公司位于浙江省杭州市余杭区仓前街道途义路27号，成立日期 2008年11月28日，上市日期2021年9月8日，公司主营业务涉及从事POCT诊断试剂的研发、生产和销 售。主营业务收入构成为：POCT产品业务及其他100.00%。 截至9月30日，博拓生物股东户数7146.00，较上期增加28.00%；人均流通股20897股，较上期减少 21.87%。2025年1月-9月，博拓生物实现营业收入3.08亿元，同比减少20.76%；归母净利润2226.32万 元，同比减少75.04%。 分红方面，博拓生物A股上市后累计派现7.98亿元。近三年，累计派现4.78亿元。 1月29日，博拓生物跌2.76%，成交额1.03亿元。 ...

Core Insights - The National Medical Products Administration of China has approved two industry standards for medical devices utilizing brain-computer interface (BCI) technology, indicating a push for high-quality development in this sector [1] - Analysts believe that the BCI field is entering a critical window for expansion from research validation to clinical and consumer applications, driven by recent innovative policies in medical devices [1] Industry Overview - Neuralink, founded by Elon Musk, is a leading player in the global BCI field, planning to scale up production of BCI devices and explore automated surgical solutions [3] - The global BCI market is projected to reach approximately $2.6 billion in 2024, with an annual growth rate of 11.5%, and is expected to expand to $3.3 billion by 2026 [3] - McKinsey forecasts that the BCI market in the medical sector could reach around $40 billion by 2030 and further grow to about $145 billion by 2040, with central nervous system disease treatment as a primary application area [3] Domestic Development - China's top-level policy design is providing crucial support for the development of BCI technology, with a goal to achieve breakthroughs in key technologies and establish a standard system by 2027 [4] - The number of companies in China's BCI sector has exceeded 200, with a projected industry scale of tens of billions of RMB by 2026 and an estimated 10-14 billion RMB by 2030 [4] - Rumors suggest that Qiangnao Technology is preparing for an IPO in Hong Kong, potentially becoming the first company among the "Hangzhou Six Little Dragons" to enter the capital market [4] Company Activities - In the A-share market, there are currently 50 listed companies in the BCI sector [5] - Botao Biological has invested in Haoshi Tianhui Technology, focusing on non-invasive BCI and mental health applications, aiming to accelerate clinical transformation and industrialization of innovative technologies [5] - Tianqi Co., Ltd. is entering the core BCI sector by investing in Suzhou Huahui Chip, focusing on high-density flexible neural electrode technology, which is crucial for domestic BCI hardware localization [6] - Innovation Medical is positioning itself in the BCI industry through its subsidiary Boling Brain Machine, which has commercialized BCI rehabilitation products [6]

证券代码：688767 证券简称：博拓生物 公告编号：2026-007 杭州博拓生物科技股份有限公司2026年第一次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的 真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 本次会议是否有被否决议案：无 一、会议召开和出席情况 （一）股东会召开的时间：2026年1月26日 （二）股东会召开的地点：杭州市余杭区仓前街道途义路27号A幢110室 （三）出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及其持有表决权数量的情 况： ■ （四）表决方式是否符合《公司法》及公司章程的规定，股东会主持情况等。 本次股东会由董事会召集，以现场投票和网络投票相结合的方式进行表决，由董事长陈音龙先生主持。 本次会议的召集、召开程序符合《公司法》《证券法》《公司章程》的规定。 （五）公司董事和董事会秘书的列席情况 1、公司在任董事7人，列席6人，三位独立董事以通讯方式出席本次会议，董事陈宇杰先生因公务安排 缺席，其余董事均现场出席； 2、公司副总经理、董事会秘书费其俊先生现场出席了本次会议；副总经理陈宇杰 ...

2026 年第一次临时股东会的 法律意见书 浙江天册律师事务所 关 于 杭州博拓生物科技股份有限公司 天册律师事务所 杭州市杭大路 1 号黄龙世纪广场 A 座 11 楼 电话：+ 86 571 8790 1110 传真：+ 86 571 8790 1500 www.tclawfirm.com 法律意见书 浙江天册律师事务所 关于杭州博拓生物科技股份有限公司 2026 年第一次临时股东会的 法律意见书 编号：TCYJS2026H0118 号 法律意见书 （1）《关于修订<公司章程>及修订、新增部分制度的议案》； 致：杭州博拓生物科技股份有限公司 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和 国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》（以下简称"《股 东会规则》"）等法律、法规和规范性文件及《杭州博拓生物科技股份有限公司章 程》（以下简称"《公司章程》"）的有关规定，浙江天册律师事务所（特殊普通 合伙）（以下简称"本所"）接受杭州博拓生物科技股份有限公司（以下简称"博 拓生物"或"公司"）的委托，指派律师参加博拓生物 2026 年第一次临时股东会， 并出具本法律意见书。 ...

证券代码：688767 证券简称：博拓生物 公告编号：2026-007 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东会召开的时间：2026 年 1 月 26 日 （二） 股东会召开的地点：杭州市余杭区仓前街道途义路 27 号 A 幢 110 室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 57 | | --- | --- | | 普通股股东人数 | 57 | | 2、出席会议的股东所持有的表决权数量 | 61,718,619 | | 普通股股东所持有表决权数量 | 61,718,619 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 41.3294 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 41.3294 | （四） 表决方式是否符合《公司法》及公司章程的规定，股东会主持情况等。 ...

1月23日盘后，杭州博拓生物科技股份有限公司(股票简称：博拓生物；股票代码：688767.SH)发布2025 年度业绩预告，受美关税政策扰动以及传染病市场周期性波动双重影响，公司2025年营业收入出现下 滑，加上研发投入以及股权激励费用等增加，预计全年归母净利润及扣非净利润均同比下降。尽管业绩 短期承压，公司管理层在近日投资者交流中明确表示，在中美关税维持相对稳定的背景下，随着差异化 竞争产品持续出新获证，公司2026年营业收入有望实现稳步增长。同时不难看出，公司正从深度和广度 上战略布局脑机接口产业，未来值得期待。 业绩短期承压，2026年拐点或至 公司业绩预告指出，2025年归母净利润的大幅下滑，主要是营业收入受美国加征关税、传染病市场需求 周期性波动的双重影响。此外，公司研发投入、股权激励费用等增加，以及财务性收益的减少导致利润 下降。尽管业绩短期承压，但公司正在积极布局新的增长点，2026年有望成为收入与业绩的拐点。 青石永隽对于产品后续研发进度的信心，得益于背靠浙江大学及南湖脑机交叉研究院的强大技术团队支 持。据公司介绍，青石永隽为南湖脑机交叉研究院孵化的脑机接口产业公司，其团队核心成员来自浙江 大 ...

- The report discusses a **quantitative timing model based on volume signals**, which indicates a "bullish" view for all major indices except the ChiNext Index as of January 23, 2026[30][31][33] - A **momentum sentiment indicator** is introduced, calculated as the proportion of stocks in the CSI 300 Index with positive returns over the past N days. The indicator is smoothed using two moving averages (N1=50, N2=35). When the short-term average exceeds the long-term average, it signals a bullish market sentiment[32][34][36] - The **moving average sentiment indicator** is based on the eight moving averages (8, 13, 21, 34, 55, 89, 144, 233). The indicator assigns values of -1, 0, or 1 based on the position of the current price relative to these moving averages. A value greater than 5 indicates a bullish signal for the CSI 300 Index[40][44] - The **cross-sectional volatility factor** is analyzed, showing that the CSI 300 Index's cross-sectional volatility increased week-over-week, indicating an improved short-term alpha environment. Conversely, the cross-sectional volatility for the CSI 500 and CSI 1000 indices decreased, suggesting a deteriorated alpha environment[45][46] - The **time-series volatility factor** is also evaluated, revealing that the time-series volatility for the CSI 300, CSI 500, and CSI 1000 indices decreased week-over-week, indicating a worsening alpha environment. Over the past quarter, the CSI 300 Index's volatility was in the lower range of the past six months, while the CSI 500 and CSI 1000 indices were in the middle range[46][49]

Core Insights - The main viewpoint of the article highlights the limitations of traditional mental health diagnostic methods and introduces a non-invasive brain-computer interface technology as a more efficient and objective solution for diagnosing conditions like depression and anxiety [1] Group 1: Current Diagnostic Methods - Current mainstream methods for diagnosing mental health issues rely on a combination of "scale assessment + comprehensive judgment by doctors," which is time-consuming and difficult to quantify [1] - In non-hospital settings, such as community screenings or corporate health management, the lack of professional psychological resources can lead to subjective biases in results [1] Group 2: Innovative Solutions - The non-invasive brain-computer interface technology offers a solution by utilizing real-time EEG signal collection and AI analysis for efficient and objective assessments [1] - The core competitive advantage of Haoshi Tianhui lies in its fully self-developed non-invasive brain-computer interface technology system, which includes high-precision AI algorithms that decode EEG signals into quantifiable emotional indicators [1] Group 3: Product Features and Efficacy - The developed system can conduct tests for depression and anxiety in as little as 90 seconds per session, achieving an accuracy rate of over 90% [1] - The system has received medical device registration certification and integrates a software platform that generates customized therapeutic music based on real-time EEG data, creating a complete "assessment-intervention-feedback" loop [1] Group 4: Market Potential and Expansion - The solution significantly reduces subjective bias and enhances screening efficiency, making it applicable in various settings such as hospitals, education, and justice [1] - Recent policy support in China for mental health diagnosis, including the incorporation of AI+EEG diagnostics into national medical guidelines, creates favorable commercialization conditions [1] - Haoshi Tianhui has initiated collaborations with medical institutions and distributors in regions like Yunnan, Guizhou, Sichuan, Jiangxi, Guangdong, Hebei, and Jiangsu-Zhejiang-Shanghai to accelerate product scaling [1] - Future plans include expanding into consumer applications through the sale of devices and consumables, as well as a system service model to achieve sustainable revenue growth [1]

（编辑 姚尧） 证券日报网1月23日讯 ，博拓生物在接受调研者提问时表示，公司认为，脑机接口产业将会是未来医疗 大健康赛道中值得长期投资的产业，并将会成为公司在医疗器械领域的重要战略布局。随着我国政策工 业和信息化部等七部门联合印发的《关于推动脑机接口产业创新发展的实施意见》明确提出，到2027年 初步建立先进的技术体系、产业体系和标准体系，2030年培育2至3家有全球影响力的领军企业，为行业 发展提供了明确指引。公司早在2023年对脑机接口方向就有研究和探索，并于2025年战略入股杭州青石 永隽，成功切入侵入式脑机接口重度难治性抑郁症治疗领域，此次参股皓世天辉则进一步完善了公司在 脑机接口领域抑郁及焦虑症等方向的检测和治疗布局。今后，公司将继续坚定在脑机接口领域的战略布 局规划，一方面公司通过旗下产投平台以自有资金进行参股或并购等方式深度参与脑机接口产业，赋能 被投企业加速产品产业及商业化进程，构建公司协同发展的医疗健康生态链；另一方面，公司拟通过设 立脑机接口产业基金，借助专业投资机构的力量及资源优势，加快推动公司在脑机接口、脑神经科学领 域的产业链布局。 ...

Core Viewpoint - Botao Bio announced the appointment of Dai Qi as the new sponsor representative for its ongoing supervision during the IPO process on the Sci-Tech Innovation Board, following a personnel change due to personal reasons of the previous representative [2] Group 1 - Botao Bio's IPO process is being supervised by Guotai Junan Securities, with the supervision period lasting until December 31, 2024 [2] - The company has not yet fully utilized the funds raised from the IPO, prompting continued oversight of the fund's storage and usage [2] - Dai Qi, the newly appointed sponsor representative, possesses substantial investment banking experience and is deemed capable of fulfilling the supervisory responsibilities [2]